Literature DB >> 11259496

Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?

A Hartmann1, P P Michel, J D Troadec, A Mouatt-Prigent, B A Faucheux, M Ruberg, Y Agid, E C Hirsch.   

Abstract

Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post-mortem brain and primary mesencephalic cell cultures treated with MPP(+). We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post-mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax-positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax-positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase-3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP(+) treatment of tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259496     DOI: 10.1046/j.1471-4159.2001.00160.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  38 in total

1.  BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

Authors:  Jordi Bové; Marta Martínez-Vicente; Benjamin Dehay; Celine Perier; Ariadna Recasens; Agnes Bombrun; Bruno Antonsson; Miquel Vila
Journal:  Autophagy       Date:  2014-03-26       Impact factor: 16.016

2.  A neuroprotective role for angiogenin in models of Parkinson's disease.

Authors:  Trent U Steidinger; David G Standaert; Talene A Yacoubian
Journal:  J Neurochem       Date:  2010-12-22       Impact factor: 5.372

3.  Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability.

Authors:  M Saldaña; E Aguilar; M Bonastre; C Marin
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

Review 4.  Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration.

Authors:  Romana Fato; Christian Bergamini; Serena Leoni; Paola Strocchi; Giorgio Lenaz
Journal:  Neurochem Res       Date:  2008-06-06       Impact factor: 3.996

Review 5.  Molecular pathways of programmed cell death in experimental Parkinson's disease.

Authors:  Miquel Vila; Celine Perier
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

6.  Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation.

Authors:  Jia-Ming Mei; Chao-Shi Niu
Journal:  Neurol Sci       Date:  2014-03-15       Impact factor: 3.307

7.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

Review 9.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease.

Authors:  Celine Perier; Jordi Bové; Du-Chu Wu; Benjamin Dehay; Dong-Kug Choi; Vernice Jackson-Lewis; Silvia Rathke-Hartlieb; Philippe Bouillet; Andreas Strasser; Jörg B Schulz; Serge Przedborski; Miquel Vila
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.